A new therapy for heart failure

Joaquim Adelino Correia Ferreira Leite Moreira

Universidade do Porto (UP), Portugal

Heart failure and pulmonary hypertension are common chronic diseases, which can lead to arrhythmias. Heart rhythm alterations contribute to a reduction in the life expectancy and quality of life of these patients.

2% of the adult population suffers from heart failure, of which 5% to 10% receive cardiac resynchronization therapy, a type of pacemaker that detects and corrects electrical impulses in the ventricles. However, one-third of people do not respond well to this therapy.

This project investigates the benefits of a new treatment, sequential cardiac resynchronization (SECRET), which has already been developed. The device will now be tested on an animal model with a new, non-invasive implantation method.

The aim is to offer treatment for patients who do not have a therapeutic solution, especially to correct the desynchronization of the left ventricle of the heart.

Sequential Cardiac Resynchronization Therapy

€369,248